At week 16 , significantly more patients taking apremilast achieved 75 % or greater reduction from baseline Psoriasis Area and Severity Index score ( PASI-75 ) ( 33.1 % ) versus placebo ( 5.3 % , P < .0001 ; primary end point ) .